Denali Therapeutics Inc. Increase (Decrease) in Other Noncurrent Liabilities
Denali Therapeutics Inc. (DNLI) reported Increase (Decrease) in Other Noncurrent Liabilities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-02-26
- Denali Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2018-12-31 was $379.00K.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2018-09-30 was $0.00.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2017-12-31 was -$226.00K.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2017-09-30 was -$154.00K.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2025 was $0.00.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2024 was $0.00.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$379.00K.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | -$379.00K 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2021-12-31 | -$322.00K 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $322.00K 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $379.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $379.00K derived: sum of 2 quarters · filed 2021-02-26 | $379.00K 10-K · filed 2021-02-26 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 | |||
| 2017-12-31 | -$226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$380.00K derived: sum of 2 quarters · filed 2020-02-27 | -$965.00K derived: sum of 3 quarters · filed 2020-02-27 | -$553.00K 10-K · filed 2020-02-27 |
| 2017-09-30 | -$154.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$739.00K derived: sum of 2 quarters · filed 2018-11-08 | -$327.00K 10-Q · filed 2018-11-08 | |
| 2017-06-30 | -$585.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$173.00K 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $412.00K 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | -$248.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |